IDH2 and acute myeloid leukemia: Secondary mutations [FLT3-ITD, DNMT3A (21), IDH, TET2 mutations] are frequently accompanying these patients. FLT3-ITD mutations are observed in 40% of NPM1 mutated AML patients.